Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

(NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more ...

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...

DexCom, Inc. (DXCM) 47th Annual Raymond James Institutional Investor Conference March 2, 2026 1:05 PM ESTCompany ParticipantsJereme Sylvain - Executive ...

Tandem Diabetes Care, Inc.’s TNDM impressive product launches are expected to bolster growth in the upcoming quarters. A strong solvency looks encouraging. However, concerns loom over fierce ...

Dexcom (Nasdaq:DXCM) today announced its plans to share new data supporting its diabetes management technology at ATTD 2026.

BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.